We report on 4 patients (1 immunocompetent, 3 immunosuppressed) in whom visceral leishmaniasis had become unresponsive to (or had relapsed after) treatment with appropriate doses of liposomal amphotericin B. Under close follow-up, full courses of pentavalent antimony were administered without life-threatening adverse events and resulted in rapid and sustained clinical and parasitological cure.
References
[1]
Petrela R, Kuneshka L, Foto E, Zavalani F, Gradoni L (2010) Pediatric visceral leishmaniasis in Albania: a retrospective nalysis of 1,210 consecutive hospitalized patients (1995–2009). PLoS Negl Trop Dis. pp. e814. doi:810.1371/journal.pntd.0000814. doi: 10.1371/journal.pntd.0000814. pmid:20838650
[2]
Buffet PA, Rosenthal E, Gangneux JP, Lightburne E, Couppie P, et al. (2011) [Therapy of leishmaniasis in France: consensus on proposed guidelines]. Presse Med 40: 173–184. doi: 10.1016/j.lpm.2010.09.023. pmid:21106333
[3]
Bourgeois N, Bastien P, Reynes J, Makinson A, Rouanet I, et al. (2010) 'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients. HIV Med 11: 670–673. doi: 10.1111/j.1468-1293.2010.00846.x. pmid:20500233
[4]
Cota GF, de Sousa MR, Rabello A (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5: e1153. doi: 10.1371/journal.pntd.0001153. pmid:21666786
[5]
Jarvis JN, Lockwood DN (2013) Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 26: 1–9. doi: 10.1097/QCO.0b013e32835c2198. pmid:23221770
[6]
de Valliere S, Mary C, Joneberg JE, Rotman S, Bullani R, et al. (2009) AA-amyloidosis caused by visceral leishmaniasis in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg 81: 209–212. pmid:19635871
[7]
Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, et al. (2008) Long-term monitoring of visceral leishmaniasis in patients with AIDS: relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 48: 13–19. doi: 10.1097/QAI.0b013e318166af5d. pmid:18300698
[8]
Sindermann H, Engel KR, Fischer C, Bommer W (2004) Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 39: 1520–1523. pmid:15546090 doi: 10.1086/425359
[9]
(2010) Control of the leishmaniases. World Health Organ Tech Rep Ser: xii-xiii, 1–186, back cover.
[10]
Mary C, Faraut F, Drogoul MP, Xeridat B, Schleinitz N, et al. (2006) Reference values for Leishmania infantum parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg 75: 858–863. pmid:17123977
[11]
Lachaud L, Chabbert E, Dubessay P, Dereure J, Lamothe J, et al. (2002) Value of two PCR methods for the diagnosis of canine visceral leishmaniasis and the detection of asymptomatic carriers. Parasitology 125: 197–207. pmid:12358417 doi: 10.1017/s0031182002002081
[12]
Davidson RN, Russo R (1994) Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 19: 560. pmid:7811891 doi: 10.1093/clinids/19.3.560
[13]
Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, et al. (2011) Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 53: e91–98. doi: 10.1093/cid/cir521. pmid:21890763
[14]
Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, et al. (2011) Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 53: e152–158. doi: 10.1093/cid/cir674. pmid:22016502
[15]
Tuon FF, Bombonatto GM, Battaglin ER, Sakumoto MH, Amato VS, et al. (2014) Reactivation of mucosal and cutaneous leishmaniasis in a renal transplanted patient. Am J Trop Med Hyg 91: 81–83. doi: 10.4269/ajtmh.13-0578. pmid:24732458
[16]
Clemente W, Vidal E, Girao E, Ramos AS, Govedic F, et al. (2015) Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect 21: 89–95. doi: 10.1016/j.cmi.2014.09.002. pmid:25636932
[17]
Brustoloni YM, Cunha RV, Consolo LZ, Oliveira AL, Dorval ME, et al. (2010) Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil. Infection 38: 261–267. doi: 10.1007/s15010-010-0022-3. pmid:20508967
[18]
Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, et al. (2009) Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 48: e16–22. doi: 10.1086/595710. pmid:19093811
